

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

POSITIVE PROFIT ALERT

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Set out below is the estimate for annual results of the Company for the year of 2021. The financial data contained in this results estimate are unaudited and the financial data contained in this results estimate are prepared in accordance with the China Accounting Standards for Business Enterprises.

I. ANNUAL RESULTS ESTIMATE FOR THE YEAR OF 2021

1. Period for the results estimate: January 1, 2021 to December 31, 2021 (the “**Reporting Period**”)
2. Results estimate: Up year-on-year
3. Results estimate is as follows:

| Item | Current Reporting Period | Same period last year |
|--|---|---------------------------|
| Net profit attributable to shareholders of the Company (the “ Shareholders ”) | Profit: RMB2,624,662,200 to RMB3,027,110,400 Growth compared with the same period of last year: 50% to 73% | Profit: RMB1,749,774,800 |
| Net profit after deducting non-operating gain or loss | Profit: RMB1,133,105,600 to RMB1,324,317,200 Growth compared with the same period of last year: 60% to 87% | Profit: RMB708,191,000 |
| Basic earnings per share | RMB3.01 per share to RMB3.47 per share | Profit: RMB2.20 per share |

II. PRELIMINARY AUDIT OF THE RESULTS ESTIMATE

The relevant data in this results estimate are only a preliminary estimate made by the finance department of the Company, which has not been reviewed by the audit committee and audited by the independent auditor of the Company.

III. REASONS FOR CHANGES IN RESULTS

During the Reporting Period, the Company's main business continued to grow, and it is expected that the revenue and the net profit attributable to the Shareholders for the year of 2021 will increase as compared with the same period of last year.

The Company's non-operating gain or loss for the year of 2020 was RMB1,041,583,800, and during the Reporting Period, the Company's non-operating gain or loss amounted to approximately RMB1,400 million to RMB1,800 million, which was mainly due to the gain on change in fair value of financial assets recognized by the Company in accordance with the new financial instrument standards and gain on transfer of equity. The financial assets invested by the Company mainly included companies of the biomedicine and medical equipment industries, which are relevant to the main businesses of the Company, and healthcare professional investment funds. In particular, the gain on change in fair value of companies in the biomedicine and medical equipment industries and those relevant to the main businesses of the Company directly or indirectly invested by the Company, recognized in accordance with the new financial instrument standards, was approximately RMB1,200 million to RMB1,600 million.

IV. OTHER RELEVANT INFORMATION

The financial data set out in this results estimate has been prepared in accordance with the China Accounting Standards for Business Enterprises.

V. RISK WARNING

This results estimate is only a preliminary estimate made by the finance department of the Company. The specific data of the annual results for the year of 2021 prepared by the Company in accordance with the China Accounting Standards for Business Enterprises or the International Financial Reporting Standards will be published on the websites of the Company, the Shenzhen Stock Exchange and The Stock Exchange of Hong Kong Limited, respectively. Investors are advised to exercise caution when making decision and pay attention to the investment risks involved.

The Shareholders and potential investors are advised to exercise caution when dealing in the Company's securities.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, January 12, 2022

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive directors of the Company are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.